Dose Exploration in Patients With Atrial Fibrillation

Trial Profile

Dose Exploration in Patients With Atrial Fibrillation

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Aug 2014

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Aspirin; Warfarin
  • Indications Cardiovascular disorders; Thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PETRO; PETRO-Ex
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Jan 2009 Extension study status changed from active, no longer recruiting to discontinued, as reported by clinicaltrials.gov.
    • 15 Jan 2009 Extension study status changed from active, no longer recruiting to discontinued, as reported by clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top